HLA-DP antibodies before and after renal transplantation

Billen, Evy V.A.; Christiaans, M. H. L.; Doxiadis, Ilias I.N.; Voorter, C. E. M.; Berg‐Loonen, Ella M. van den

doi:10.1111/j.1399-0039.2009.01428.x

Cited by 41 publications

(41 citation statements)

References 26 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bryan et al reported 42% sensitization to HLA-Cw in sensitized patients, which was significantly lower than sensitization to HLA-A (80%) and HLA-B (83%), similar to our results [13]. Billen et al reported 11of 133 patients (8%) on the waiting list had anti-HLA-DP antibodies by Luminex and pregnancy was the most important stimulator for development of anti-HLA-DP antibody [14]. The frequency of anti-HLA-DP antibody was also similar in our study (8%) seen in 87 of 1069 patients, constituting 35% of the sensitized patients, which is lower than anti-HLA-DR (66%) and DQ (69%) antibodies.…”

Section: Discussionsupporting

confidence: 93%

Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients

et al. 2012

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients

et al. 2012

View full text Add to dashboard Cite

“…Recent studies demonstrate the clinical relevance of determining epitope specificities of class II antibodies and the role of epitopes in class II matching (15)(16)(17)(18)(19)(20); defining compatibility at the allele level is beneficial for sensitized transplant candidates with class II reactive antibodies (21).…”

Section: Introductionmentioning

confidence: 99%

Should HLA Mismatch Acceptability for Sensitized Transplant Candidates Be Determined at the High-Resolution Rather Than the Antigen Level?

Duquesnoy

Kamoun

Baxter-Lowe

et al. 2015

American Journal of Transplantation

View full text Add to dashboard Cite

“…Determination of unacceptable human leukocyte antigen (HLA) antigen mismatches, risk assessment by assessing the HLA antibodies, combination of desensitization and careful monitoring of posttransplant immunologic events contributed to improve allograft and patient survival (2)(3)(4). For the histocompatibility tests, in addition to conventional complement-dependent lymphocytotoxicity (CDC) crossmatching test (XM) and low resolution HLA typing, technical developments in XM using flow cytometry and HLA antibody detection methods using luminex microbead array have helped to further understand and identify the immunological components involved in alloimmune response (5)(6)(7)(8)(9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

Results of Questionnaire Survey of Current Immune Monitoring Practice of Transplant Clinicians and Clinical Pathologists in Korea: Basis for Establishment of Harmonized Immune Monitoring Guidelines

Kang

Choi

Park

et al. 2018

Korean J Transplant

View full text Add to dashboard Cite

Detection of significant alloimmune response, which affects graft function and survival by effective immune monitoring, is critical for treatment decision making. However, there is no consensus regarding immune monitoring (IM) for kidney transplantation (flow KT) in Korea. The IM protocol may be affected by the level of immunological risk, the methods of desensitization and the availabilities of resources such as laboratory support and cost of tests. Questionnaire surveys designed to identify the current practi- Until now, the immunological monitoring of alloimmune responses are focused on the detection of rejection events in practice than detection of adverse immune activity which might be preceded clinically or pathologically evident rejection signs. It might be rather because there were no reliable and well validated laboratory methods to be applicable.However, luminex bead technologies used for the detection of antibodies in antigen, allele or epitope levels for HLA(7-9) and non-HLA systems(15), and molecular technologies to detect transcript signatures of diverse immunologic changes are broadening our choice of tests(16-18).And it is continuously reflected on diagnostic criteria such as Banff criteria (19,20). However, the diagnostic criteria does not specify the practical way of immune monitoring in real world, so, there is no standardized guidelines and is Immune monitoring protocolsAbout 28% (9/32) of clinicians from 6 institutes (6/25, 24%) are performing protocol biopsies at various time points and the number of biopsy depending on the level of immunological risks (Fig. 3). When higher the risk, more frequent biopsies are being performed within posttransplant 12 weeks (Fig. 4). Clinicians are applying different combinations of HLA antibody tests in different time points and also depending on the level of immunological risks. Antibody monitoring is being performed frequently at posttransplant 3∼4 weeks, 24 weeks and yearly (Fig. 5). Antibody screening test is used for low risk patients, however for high risk patients, HLA antibody phenotyping or SAB identification tests are used more frequently (Fig. 6). The suggested time points of HLA antibody monitoring test in patients waiting for kidney transplantation was questioned regardless of current protocols (Fig. 7). Twenty-four out of 26 (92%) respondents answered that the presence of HLA antibody needed to be checked at registration in KONOS regardless of immunological risk levels, and for living donor kidney transplant (LDKT) candidates, it is suggested to do within pre-transplant 4 weeks. Twelve (46%) respondents replied that the monitoring of HLA antibody is necessary if the patients had recent transfusion or pregnancy episodes.As on-demand test when the rejection is suspected clinically, 70% (22/32) of respondents answered proceeding to HLA antibody test but 15% (5/32) answered to do HLA antibody test when the pathologic finding of AMR in biopsy identified (Fig. 8).2. sponses needs to be cautious because it may be rather because not all the instit...

show abstract

HLA-DP antibodies before and after renal transplantation

Cited by 41 publications

References 26 publications

Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients

Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients

Should HLA Mismatch Acceptability for Sensitized Transplant Candidates Be Determined at the High-Resolution Rather Than the Antigen Level?

Results of Questionnaire Survey of Current Immune Monitoring Practice of Transplant Clinicians and Clinical Pathologists in Korea: Basis for Establishment of Harmonized Immune Monitoring Guidelines

Contact Info

Product

Resources

About